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C-reactive protein and albumin as predictors of all-cause and
cardiovascular mortality in chronic kidney disease.
Background. High C-reactive protein (CRP) and hypoalbu-
minemia are associated with increased risk of mortality in pa-
tients with kidney failure. There are limited data evaluating the
relationships between CRP, albumin, and outcomes in chronic
kidney disease (CKD) stages 3 and 4.
Methods. The Modification of Diet in Renal Disease
(MDRD) Study was a randomized controlled trial conducted
between 1989 and 1993. CRP was measured in frozen samples
taken at baseline. Survival status and cause of death, up to De-
cember 31, 2000, were obtained from the National Death Index.
Multivariable Cox models were used to examine the relation-
ship of CRP [stratified into high CRP ≥3.0 mg/L (N = 414) ver-
sus low CRP<3.0 mg/L (N = 283)], and serum albumin, with
all-cause and cardiovascular mortality.
Results. Median follow-up time was 125 months, all-cause
mortality was 20% (N = 138) and cardiovascular mortality was
10% (N = 71). In multivariable analyses adjusting for demo-
graphic, cardiovascular and kidney disease factors, both high
CRP (HR, 95% CI = 1.56, 1.07–2.29) and serum albumin (HR =
0.94 per 0.1 g/dL increase, 95% CI = 0.89-0.99) were indepen-
dent predictors of all-cause mortality. High CRP (HR 1.94, 95%
CI 1.13–3.31), but not serum albumin (HR 0.94, 95% CI 0.87–
1.02), was an independent predictor of cardiovascular mortality.
Conclusion. Both high CRP and low albumin, measured in
CKD stages 3 and 4, are independent risk factors for all-cause
mortality. High CRP, but not serum albumin, is a risk factor
for cardiovascular mortality. These results suggest that high
CRP and hypoalbuminemia provide prognostic information in-
dependent of each other in CKD.
C-reactive protein (CRP) levels are elevated in pa-
tients with kidney failure [1] and are independent predic-
tors of cardiovascular mortality in this patient population
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[2–5]. Patients with chronic kidney disease (CKD) stages
3 and 4 also have a high burden of cardiovascular disease
and are at higher risk of cardiovascular disease mortality
[6–9]. A recent study showed that high CRP is associated
with increased risk of coronary events in women with cre-
atinine clearance less than 74 mL/min and no history of
cardiovascular disease [10]. There are no studies of which
we aware that have evaluated whether CRP is associated
with future risk of either all-cause mortality or cardiovas-
cular disease mortality in CKD stages 3 and 4.
Hypoalbuminemia, is highly prevalent in kidney fail-
ure and is associated with an increased mortality risk in
this population [11]. In theory, hypoalbuminemia may re-
flect either the inflammatory or nutritional status of pa-
tients with kidney failure. Some studies in patients with
advanced kidney disease or kidney failure have suggested
that after adjustment for CRP, hypoalbuminemia is not a
risk factor for cardiovascular disease [3, 4, 12]. The rela-
tionship between CRP, albumin, and outcomes are yet to
be evaluated in the earlier stages of CKD.
We have previously shown in cross-sectional analyses
from the Modification of Diet in Renal Disease (MDRD)
Study randomized cohort that although CRP levels ap-
proximated those in a general population sample and
were not associated with level of glomerular filtration rate
(GFR), they were positively associated with cardiovascu-
lar disease and negatively associated with serum albumin
[13].
The aims of the present study were therefore to evalu-
ate CRP and albumin, and the relationship between the
two, as risk factors for all-cause mortality and cardio-
vascular disease mortality in long-term follow-up of the
MDRD Study randomized cohort.
METHODS
Study population
Details of the MDRD Study have been published pre-
viously [14]. In brief, it was a randomized controlled trial
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of 840 patients with predominantly nondiabetic kidney
disease and reduced GFR, conducted between 1989 and
1993, to study the effects of dietary protein restriction and
strict blood pressure control on the progression of kidney
disease. All patients entering baseline had mean arterial
pressures ≤125 mm Hg, were 18 to 70 years of age and
had CKD with serum creatinine 1.4 to 7.0 mg/dL (123.8
to 618.8 lmol/L) (men) and 1.2 to 7.0 mg/dL (106.08 to
618.8 lmol/L) (women). Other exclusion criteria were a
history of insulin-requiring diabetes, class III or IV con-
gestive heart failure, renal artery stenosis, kidney trans-
plantation, and frequent hospitalizations.
A total of 585 patients with a baseline GFR of
25 to 55 mL/min/1.73 m2 were randomized into study
A and 255 patients with a baseline GFR of 13 to
24 mL/min/1.73 m2 were randomized to study B. The
etiology of kidney diseases was 25% polycystic kid-
ney disease, 25% glomerular diseases, and 50% other
causes. A history of coronary heart disease, cerebrovas-
cular disease, and peripheral vascular disease was ob-
tained through patient self-report and medical record
review.
Survival status, through December 31, 2000, was ascer-
tained by review of death certificates using the National
Death Index (NDI). A death was ascribed to cardiovas-
cular disease if the primary cause of death was cardio-
vascular disease [International Classification of Diseases,
9th revision (ICD-9 code 390-459)] or if kidney disease
or diabetes were listed as the primary cause of death and
cardiovascular disease (ICD-9 code 390-459) was the sec-
ondary cause of death. Data collection procedures were
approved by the Cleveland Clinic and Tufts-New England
Medical Center Institutional Review Boards.
Laboratory measurements
Fasting serum samples were drawn at baseline from
801 participants of the MDRD Study cohort and stored
at −70◦C for future analyses. Samples underwent two
freeze/thaw cycles before being assayed for CRP. High-
sensitivity CRP was measured, at the University of
Washington, Seattle, with a Dade Behring BN II neph-
elometer (Deerfield, IL, USA) using particle-enhanced
technology. The detection limit of this method is
0.01 mg/dL with inter-run coefficients of variation for the
low- and high-quality control samples of 3.5% and 3.0%,
respectively.
Other relevant clinical and biochemical variables were
measured as described in prior reports [15]. GFR was as-
sessed by the kidney clearance of 125I-iothalamate after
subcutaneous injection. Level of proteinuria (g/day) was
estimated from 24-hour urine samples. Serum albumin
was measured at baseline by dye-binding using bromocre-
sol green reagents and an Astra 8 analyzer (Beckman
Instruments, Fullerton, CA, USA).
Statistical analyses
We have previously demonstrated an association be-
tween CRP and prevalent cardiovascular disease in cross-
sectional analyses of the MDRD Study cohort [13].
Therefore, for the present analysis, we restricted the
study sample to patients without history of preexisting
atherosclerotic cardiovascular disease (defined as history
of coronary artery disease, cerebrovascular disease, or
peripheral vascular disease) at baseline so as to remove
confounding from prevalent vascular disease; thus, our
sample size for this study was 697 (study A = 487 and
study B = 210).
Baseline characteristics by level of CRP
The study sample was divided into two groups based
on level of CRP (high CRP ≥3.0 mg/L versus low
CRP<3.0 mg/L) as defined in a recent guideline from
the Centers for Disease Control and Prevention and the
American Heart Association [16]. The distribution and
normality of variables of interest were evaluated using
box plots and histograms. Summary statistics are pre-
sented as percentages for categoric data, mean ± stan-
dard deviation for approximately normally distributed
continuous variables, and median (interquartile range)
for skewed continuous variables. Differences between
the groups were tested using the chi-square test for cate-
goric variables, Student t test for approximately normally
distributed continuous variables, and the Mann-Whitney
test for skewed continuous variables.
CRP, albumin, and outcomes
Incidence rates for all-cause mortality and cardiovas-
cular disease mortality were plotted by decile of CRP.
Kaplan-Meier survival plots for differences in survival
between patients with high versus low CRP were com-
pared using the log rank test. Cox proportional hazards
models, stratified by study, were used to evaluate the re-
lationship of high CRP and albumin with all-cause and
cardiovascular disease mortality, initially without adjust-
ment, and subsequently adjusting for several groups of
covariates.
The first multivariable model, model 1, included CRP
(0, low vs. high) and albumin. In model 2 we added
age, race, gender, and randomization assignments to dif-
ferent blood pressure goals and protein diets. Model 3
adjusted for traditional cardiovascular disease risk fac-
tors: smoking status, diabetes, body mass index, systolic
blood pressure, low-density lipoprotein (LDL) and high-
density lipoprotein (HDL) cholesterol, in addition to the
variables in model 2. Model 4 adjusted for variables in
model 3 as well as etiology of kidney disease. Models
5 and 6 contained all the variables in model 4 but ex-
cluded albumin and CRP, respectively. We did not adjust
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for GFR as this is taken into account by the stratification
variable-study. However, since stratifying by study may
not fully adjust for level of kidney function, we repeated
the multivariable Cox models adjusting for baseline GFR
as a continuous variable. In addition, an interaction term
was tested between CRP and albumin as continuous vari-
ables in multivariable Cox models with all-cause mortal-
ity and cardiovascular disease mortality as outcomes.
The 95% CIs were calculated for the hazard ratios
(HRs). A CI that excludes 1.0 indicates a significant re-
lationship of CRP and albumin with outcomes (all-cause
and cardiovascular disease mortality). The HR for albu-
min is per each 0.1 g/dL increase of albumin. Proportional
hazards assumptions were tested using log minus log sur-
vival plots, and plots of Schoenfeld residuals versus sur-
vival time.
Sensitivity analyses
Because of the concern for insufficient statistical power
in the evaluation of the relationship between cardiovas-
cular disease mortality and albumin, a sensitivity analysis
was performed including those patients with history of
cardiovascular disease.
RESULTS
The mean ± standard deviation age of the study cohort
was 51 ± 12 years. Fifty eight percent were males, 85%
were white, and the prevalence of noninsulin-dependent
diabetes was 4%. Minimum and maximum GFR was 12
to 55 mL/min/1.73 m2 with a mean ± SD GFR of 32.9 ±
12.2 mL/min/1.73 m2. Minimum and maximum CRP was
0.1 to 73.7 mg/L with mean of 4.5 ± 6.3 mg/L. Mean ± SD
albumin was 4.0 ± 0.4 g/dL with minimum and maximum
of 3 to 5 g/dL.
Baseline characteristics of MDRD Study sample by level
of CRP
Subjects in the high CRP group were older (P < 0.001),
and more likely to be female (P = 0.001) (Table 1). High
CRP was associated with higher body mass index (P <
0.001), and lower levels of serum albumin (P < 0.001).
High CRP was also associated with high prevalence of
traditional cardiovascular disease risk factors, including
diabetes (P < 0.001), high systolic blood pressure (P <
0.001), total cholesterol (P = 0.03), triglycerides (P <
0.001), and low HDL cholesterol (P = 0.04). There was
a higher prevalence of glomerular or other diseases as a
cause of kidney disease, as opposed to polycystic kidney
disease, in the high CRP group (P = 0.002). Level of
GFR and proteinuria did not differ between the CRP
groups.
Table 1. Characteristics of patients with chronic kidney disease
according to levels of C-reactive protein (CRP): Modification of Diet
in Renal Disease Study (MDRD) Study
Low CRP <3 mg/L High CRP ≥3 mg/L
N = 414 N = 283
C-reactive protein mg/La 1.2 (1.2) 6.8 (5.4)
Demographic factors
Age yearsb 48.0 ± 12.5 54.4 ± 10.6c
Male% 63 51c
White% 85 85
Diabetes% 2 8c
Current smoker% 10 9
Cardiovascular risk factors
Systolic blood pressure
mm Hgb
128.8 ± 15.9 134.8 ± 18.9c
Diastolic blood pressure
mm Hgb
81.6 ± 9.9 81.3 ± 10.1
Total cholesterol mg/dLb 214.1 ± 45.2 222.0 ± 46.4c
Triglycerides mg/dLb 153.1 ± 120.1 201.2 ± 150.1c
Low-density-lipoprotein
cholesterol mg/dLb
146.4 ± 41.5 148.7 ± 42.0
High-density-lipoprotein
cholesterol mg/dLb
41.5 ± 13.9 39.2 ± 15.1c
Nutritional factors
Body mass index kg/m2b 25.5 ± 3.7 29.2 ± 4.6c
Albumin g/dLb 4.1 ± 0.4 3.9 ± 0.3c
Kidney disease factors
Glomerular filtration
rate mL/min/1.73 m2b
32.5 ± 12.5 33.5 ± 11.8
Proteinuria g/daya 0.3 (1.4) 0.3 (1.5)
Kidney disease category %b
Glomerular disease 30 18c
Polycystic kidney
disease
30 34
Other 40 48
aMedian (interquartile range); bMean ± standard deviation; cP < 0.05.
CRP, albumin, and all-cause mortality
Median follow-up time was 125 months and all-cause
mortality was 20% (N = 138). Higher levels of CRP
were associated with higher rates of all-cause mortality
(Fig. 1). Kaplan-Meier survival curves demonstrated that
high CRP (≥3.0 mg/L) was associated with higher all-
cause mortality than low CRP (<3.0 mg/L) (P < 0.001)
(Fig. 2). In unadjusted Cox regression models, high CRP
was associated with a greater than twofold increase in the
risk of all-cause mortality (P < 0.001) while a 0.1 g/dL in-
crease in albumin was associated with an 11% decrease
in the risk of all-cause mortality (P < 0.001) (Table 2).
In multivariable Cox models adjusting for study, demo-
graphic, traditional cardiovascular disease risk factors,
type of kidney disease, and randomization to different
protein diets and blood pressure strata, high CRP (P =
0.02) and low serum albumin (P = 0.03) remained in-
dependent predictors of all-cause mortality. High CRP
was associated with a 56% increased risk of all-cause
mortality, and a 0.1g/dL increase in albumin was asso-
ciated with 6% decreased risk of all-cause mortality. The
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Fig. 1. Crude all-cause and cardiovascular
mortality rates by decile of C-reactive protein.
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Fig. 2. Kaplan-Meier survival curves showed that high C-reactive pro-
tein (≥3.0 mg/L) was associated with higher all-cause mortality than
low C-reactive protein (<3.0 mg/L) (log rank test, P = < 0.0001).
analysis was repeated after adjusting for GFR instead of
stratifying by study. In this model, CRP (HR, 95% CI
= 1.57, 1.07-2.29), and albumin (HR, 95% CI = 0.95,
0.90-1.00) remained independent predictors of all-cause
mortality. The interaction term between CRP and albu-
min was not statistically significant for all-cause mortality
(P = 0.85).
CRP, albumin, and cardiovascular disease mortality
Cardiovascular disease mortality was 10% (N = 71).
In unadjusted analysis, increasing levels of CRP were as-
sociated with increasing rates of cardiovascular disease
mortality (Fig. 1). Kaplan-Meier survival curves demon-
strated that high CRP was associated with higher car-
diovascular disease mortality than low CRP (P < 0.001)
(Fig. 3). In unadjusted Cox regression models, high CRP
was associated with an almost threefold increase in the
risk of cardiovascular disease mortality (P < 0.001) and a
0.1 g/dL increase in serum albumin was associated with an
Table 2. C-reactive protein (CRP) and serum albumin as predictors
of all-cause mortality
High CRP (≥3 mg/L)
versus Serum albumin
low CRP (<3 mg/L) g/dL
HR 95% CI HRa 95% CI
Unadjusted 2.36 1.68, 3.32 0.89 0.85, 0.94
Adjusted
Model 1 2.20 1.56, 3.11 0.91 0.86, 0.95
Model 2 1.74 1.22, 2.49 0.92 0.87, 0.96
Model 3 1.62 1.11, 2.38 0.94 0.89, 0.99
Model 4 1.56 1.07, 2.29 0.94 0.89, 0.99
Model 5 1.57 1.08, 2.30 — —
Model 6 — — 0.94 0.89, 0.99
aHazard ratio for each 0.1 g/L increase in serum albumin.
Model 1, albumin and CRP, and stratified by study; model 2, variables in model
1+ age, gender, race, randomization to different protein diets, and blood pressure
strata; model 3, variables in model 2+ diabetes, current smoking, low-density
lipoprotein cholesterol, high-density lipoprotein cholesterol, body mass index,
and systolic blood pressure; model 4, variables in model 3 + etiology of kidney
disease; model 5, variables in model 4, excluding albumin; model 6, variables in
model 4, excluding CRP.
11% reduction in the risk of cardiovascular disease mor-
tality (P < 0.001) (Table 3). High CRP (P = 0.02) was
associated with a twofold increased risk of cardiovascu-
lar disease mortality after adjusting for serum albumin,
demographic, cardiovascular disease, and kidney disease
risk factors, and randomization to different protein diets
and blood pressure assignments while the HR for albu-
min was no longer significant. The analysis was repeated
after adjusting for GFR. In this model, CRP (HR, 95%
CI = 1.99, 1.16-3.40), but not albumin (HR, 95% CI =
0.95, 0.88-1.03), was an independent predictor of cardio-
vascular disease mortality. The interaction term between
CRP and albumin was not statistically significant for car-
diovascular disease mortality (P = 0.90).
Sensitivity analysis
Since the lack of significance with albumin may be due
to insufficient statistical power we performed a sensitivity
analysis, including those patients with a history of cardio-
vascular disease. Although the number of cardiovascular
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Fig. 3. Kaplan-Meier survival curves showed that high C-reactive pro-
tein (≥3.0 mg/L) was associated with higher cardiovascular mortality
than low C-reactive protein (<3.0 mg/L) (log rank test, P = <0.0001).
Table 3. C-reactive protein (CRP) as a predictor of cardiovascular
mortality in patients with chronic kidney disease
High CRP (≥3 mg/L)
versus Serum albumin
low CRP (<3 mg/L) g/dL
HR 95% CI HRa 95% CI
Unadjusted 2.80 1.72, 4.53 0.89 0.83, 0.95
Adjusted
Model 1 2.62 1.61, 4.27 0.90 0.84, 0.97
Model 2 2.13 1.28, 3.53 0.91 0.85, 0.98
Model 3 1.97 1.15, 3.37 0.94 0.88, 1.02
Model 4 1.92 1.12, 3.29 0.94 0.87, 1.02
Model 5 1.94 1.13, 3.31 — —
Model 6 — — 0.94 0.87, 1.02
aHazard ratio per each 0.1 g/L increase in serum albumin.
Model 1, albumin and CRP, and stratified by study; model 2, variables in model
1+ age, gender, race, randomization to different protein diets and blood pressure
strata; model 3, variables in model 2+ diabetes, current smoking, low-density
lipoprotein cholesterol, high-density lipoprotein cholesterol, body mass index,
and systolic blood pressure; model 4, variables in model 3+ etiology of kidney
disease; model 5, variables in model 4, excluding albumin; model 6, variables in
model 4, excluding CRP.
disease events increased to 118, the HR for albumin re-
mained insignificant in multivariable analysis after ad-
justment for the above listed covariates and history of
cardiovascular disease (HR, 95% CI = 0.95, 0.89–1.03).
DISCUSSION
High CRP and serum albumin are independent predic-
tors of all-cause mortality in patients with CKD stages 3
and 4. This relationship was independent of each other
and demographic, cardiovascular and kidney disease fac-
tors. High CRP, but not serum albumin, was an indepen-
dent risk factor for cardiovascular disease mortality in
this study population.
Patients with CKD are at high risk for cardiovascular
disease even prior to initiation of dialysis [6–8, 17]. Eighty
percent of incident hemodialysis patients have abnormal
findings on their echocardiograms and 50% have clinical
evidence of cardiovascular disease [18, 19]. Thus, the de-
velopment of cardiovascular disease is an early event in
the progression of kidney disease. Inflammatory mark-
ers in general, and CRP in particular, are independent
predictors of the future risk of outcomes both in the gen-
eral population and among patients with kidney failure.
Several prospective studies have demonstrated that sin-
gle measurements of CRP can predict all-cause mortality
and cardiovascular disease mortality in the general popu-
lation [20–22], postkidney transplant [23], and in patients
with kidney failure treated with peritoneal dialysis [2,
24], and hemodialysis [3, 4, 25]. A recent analysis from
the Nurses’ Health Study showed that CRP was an in-
dependent predictor of coronary events among women
with creatinine clearance ≤74 mL/min and no history of
preexisting cardiovascular disease [10]. Several lines of
evidence suggest that CRP may not be merely a marker
of inflammation but may in fact mediate several key pro-
cesses in the development of atherosclerosis including
plaque initiation, formation, and rupture [26].
We postulated that since the development of cardio-
vascular disease is an early event in the progression of
CKD, levels of CRP measured early in the disease may
be associated with future outcomes. Our findings demon-
strate a significant association between CRP and all-cause
mortality and cardiovascular disease mortality. We have
previously shown that CRP is associated with an unfa-
vorable cardiovascular risk profile in the MDRD Study
cohort [13]. Studies in the general population and in
patients with kidney failure have also found an associ-
ation between CRP and several traditional cardiovascu-
lar disease risk factors [27–30]. However, the association
between CRP and outcomes in our study remained sig-
nificant after adjusting for these cardiovascular disease
risk factors as well as adjustment for demographic, nu-
tritional, and kidney disease factors. These data suggest
an early involvement of inflammatory processes in the
development of cardiovascular disease in patients with
CKD.
Hypoalbuminemia is a powerful predictor of mortal-
ity in patients with kidney failure [11, 32–34]. The in-
terrelationships between inflammation, nutritional sta-
tus, and outcomes in patients with kidney failure has led
some authors to speculate on the existence of a malnu-
trition, inflammation, atherosclerosis complex syndrome
in this population [12, 35]. It has been suggested that
the association between serum albumin levels and car-
diovascular disease, in patients with kidney disease, may
in part reflect the role of inflammation in inducing the
malnutrition that is highly prevalent in these patients
[12]. Postulated mechanisms for the association between
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inflammation and malnutrition, include appetite suppres-
sion and enhanced protein catabolism by proinflamma-
tory cytokines. Some studies have in fact shown that al-
bumin, but not CRP, was an independent predictor of
mortality in 6-month follow-up [36]. The authors postu-
lated that all or part of the association between CRP and
outcomes may be mediated via the deleterious effects of
proinflammatory cytokines on nutritional status.
Other studies have however suggested that hypoalbu-
minemia is simply a reflection of the negative acute phase
response, and that serum albumin levels may be more
indicative of underlying inflammation, rather than nutri-
tional status, especially in patients with kidney disease.
For example, a recent study demonstrated that although
both serum albumin levels and protein malnutrition, mea-
sured as nitrogen index, were independent predictors of
all-cause mortality in a cohort of patients starting dialysis
[37], only serum albumin and not protein malnutrition
was a significant predictor for the occurrence of new vas-
cular events. In addition, other studies have suggested
that when one includes CRP in a model predicting mor-
tality, albumin loses its association with outcomes [3, 4,
12].
In the present study both CRP and albumin remained
significant predictors of all-cause mortality when in-
cluded simultaneously in the regression model. This
finding suggests that albumin levels provide additional
prognostic information to that contributed by CRP in
this population. Possible mechanisms include a role for
albumin as a marker of a process that is distinct from
inflammation (e.g., malnutrition) and/or that albumin re-
flects a separate pathway from CRP in the inflammatory
process. Irrespective of the underlying mechanism, the
recognition that both are separate and significant risk fac-
tors for all-cause mortality is important.
In our study sample albumin levels were not indepen-
dently associated with cardiovascular disease mortality.
These results are consistent with a study by Zimmerman
et al [3], which showed that in 280 stable hemodial-
ysis patients, high CRP and low serum albumin were
independent predictors of 2-year all-cause mortality;
however, only CRP was associated with cardiovascular
disease death. Although we cannot be certain, in our
study the lack of association between serum albumin and
cardiovascular disease mortality may be due to limited
statistical power. The fact that the HR for serum albu-
min and cardiovascular disease mortality was similar to
the HR for albumin and all-cause mortality supports this
premise. Therefore, although one may speculate that if
level of albumin is a reflection of malnutrition, it is more
likely to be associated with all-cause mortality in com-
parison with cardiovascular disease mortality, we do not
have conclusive data in support of this hypothesis.
There are several strengths to our study. The MDRD
Study is a good population to assess the relationship be-
tween CRP and albumin and risk of all-cause and car-
diovascular disease mortality in the setting of kidney dis-
ease. At baseline, this large cohort of patients with CKD
stages 3 and 4, spans a wide range of kidney function, and
consists of subjects who are predominantly nondiabetic,
and are neither appreciably malnourished nor acutely ill
[38]. This minimizes the limitation of confounding due to
comorbid conditions such as malnutrition, diabetes, and
preexisting cardiovascular disease. However, it must be
acknowledged that these study findings are generalizable
to predominantly white patients with nondiabetic kidney
disease.
The limitations include the use of a single baseline mea-
surement of CRP to predict events several years in the
future. However there are several precedents for this in
the general population as well as in patients with kidney
failure [20, 22, 39]. In addition, a recent study demon-
strated that in serial measurements, levels of CRP were
fairly stable with minimal intraperson variation over sev-
eral years [40]. It must be acknowledged that additional
CRP measurements may have enabled more precise as-
sessment of the relationship between CRP and outcomes.
Frozen samples were used for the measurement of CRP;
however, there is a precedent for using frozen stored sam-
ples to analyze CRP and CRP appears to be stable de-
spite extended storage [41–44] and up to four freeze-thaw
cycles [44].
CONCLUSION
CRP and albumin measured in stages 3 and 4 CKD are
predictive of all-cause mortality. While inflammation may
account, in part, for the relationship between albumin
and outcomes, our results suggest that additional path-
ways may mediate this association. These findings may
have implications for early identification and risk strati-
fication of vulnerable patients and for the development
for targeted interventions to reduce the risk of mortality
in this patient population.
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